Get the Stockscreener App
1.01
1.94%
-0.02
After Hours:
1.01
Hoth Therapeutics Inc stock is traded at $1.01, with a volume of 316.74K.
It is down -1.94% in the last 24 hours and up +31.15% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
316.74K
Relative Volume:
0.75
Market Cap:
$15.67M
Revenue:
-
Net Income/Loss:
$-12.16M
P/E Ratio:
-0.9486
EPS:
-1.0647
Net Cash Flow:
$-9.68M
1W Performance:
-2.88%
1M Performance:
+31.15%
6M Performance:
-24.06%
1Y Performance:
-11.40%
1-Day Range:
$1.00
$1.065
1-Week Range:
$0.9601
$1.065
52-Week Range:
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.01 | 15.98M | 0 | -12.16M | -9.68M | -1.0647 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics (NASDAQ: HOTH) Is Heating Up – New Site Added - Bitget
Hoth Therapeutics Integrates OpenAI API to Advance HT-KIT Oncology Program for Mast Cell-Derived Cancers - geneonline.com
Analyst Maintains Buy Rating for Hoth Therapeutics (HOTH) | HOTH Stock News - GuruFocus
EPS Watch: Whats the fair value of Hoth Therapeutics Inc stockTrade Volume Report & Smart Allocation Stock Tips - baoquankhu1.vn
Hoth Therapeutics Deploys OpenAI API to Support Development of HT-KIT - Contract Pharma
Hoth Therapeutics deploys Openai API to advance development of orphan HT-KIT oncology program - marketscreener.com
AI joins fight against rare cancers in Hoth’s HT-KIT program - Stock Titan
EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers - Benzinga
HOTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HOTH.O| Stock Price & Latest News - Reuters
Aug Selloffs: Is Hoth Therapeutics Inc stock trending bullishPortfolio Risk Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
HOTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hoth Therapeutics adds clinical site for skin toxicity trial - Investing.com India
Hoth Therapeutics adds clinical site for skin toxicity trial By Investing.com - Investing.com Australia
Hoth Therapeutics accelerates HT-001 trial enrollment with new clinical site as patient demand increases - marketscreener.com
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES - PR Newswire
Performance Recap: Will Lufax Holding Ltd Depositary Receipt benefit from geopolitical trendsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
Aug Reactions: Whats the outlook for Hoth Therapeutics Incs sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Will Hoth Therapeutics Inc. announce a stock splitCPI Data & Technical Pattern Recognition Alerts - mfd.ru
HOTH Should I Buy - Intellectia AI
Is Hoth Therapeutics Inc. stock trending bullishJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - mfd.ru
Hoth Therapeutics receives U.S. notice of allowance for novel exon-skipping therapy targeting allergic diseases - marketscreener.com
Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases - TradingView
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases - PR Newswire
Hoth’s obesity treatment outperforms semaglutide in preclinical study - Investing.com Australia
Why Hoth Therapeutics Inc. stock is a must watch in 2025Trade Volume Summary & Pattern Based Trade Signal System - mfd.ru
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics - Intellectia AI
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Asianet Newsable
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits
Hoth Therapeutics announces groundbreaking positive results: HT-VA GDNF surpasses Semaglutide in weight loss - marketscreener.com
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment - Intellectia AI
Hoth Therapeutics rises as early obesity‑drug data in mice shows promise - TradingView
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model - PR Newswire
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Benzinga
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - Eastern Progress
Travel Stocks: What is CROXs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets - marketscreener.com
Biotech Hoth rejects crypto rumor, says exposure never topped $350K - Stock Titan
Hoth Therapeutics (HOTH) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aug Final Week: Can KVACW outperform in the next rallyTrade Analysis Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Hoth Therapeutics stock rises after filing patents for cancer therapy skin toxicity treatments - Investing.com Nigeria
Risk Analysis: Can BSVN expand into new marketsMarket Activity Report & Verified Stock Trade Ideas - baoquankhu1.vn
Market Leaders: What are analysts price targets for HOVRWJuly 2025 Volume & Safe Capital Growth Stock Tips - baoquankhu1.vn
Pharma News: What are the risks of holding Aduro Clean Technologies IncMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bear Alert: Can National Energy Services Reunited Corp Equity Warrant keep up with sector leaders2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Hoth Therapeutics stock rises after positive interim trial results By Investing.com - Investing.com Australia
Hoth reports positive interim results for cancer skin therapy By Investing.com - Investing.com Nigeria
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half - Benzinga
Hoth Therapeutics stock rises after positive interim trial results - Investing.com
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):